El Salvador vs South-East Asia (WHO region): Hypertension effective treatment coverage (controlled hypertension)
El Salvador
39.4%
in 2019
South-East Asia (WHO region)
13.6%
in 2019
El Salvador rank
9th
South-East Asia (WHO region) rank
9th
Hypertension effective treatment coverage (controlled hypertension) over time
- El Salvador
- South-East Asia (WHO region)
How they compare
El Salvador currently reports 39.4% against 13.6% in South-East Asia (WHO region), a difference of 25.8%.
That makes El Salvador's figure about 2.9 times South-East Asia (WHO region)'s.
Across all 30 years both countries report, El Salvador has been ahead every year.
El Salvador ranks 9th and South-East Asia (WHO region) ranks 9th of 193 countries.
El Salvador has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | El Salvador | South-East Asia (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 14.0% | 2.5% | 11.5% | El Salvador |
| 2000s | 23.3% | 5.8% | 17.6% | El Salvador |
| 2010s | 35.5% | 10.9% | 24.5% | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hypertension effective treatment coverage (controlled hypertension), El Salvador or South-East Asia (WHO region)?
- El Salvador, at 39.4% against 13.6% in South-East Asia (WHO region) as of 2019.
- What is the difference in hypertension effective treatment coverage (controlled hypertension) between El Salvador and South-East Asia (WHO region)?
- 25.8%, with El Salvador ahead.
- How many years of comparable data are there for El Salvador and South-East Asia (WHO region)?
- 30 years are reported by both, from 1990 to 2019.
- How do El Salvador and South-East Asia (WHO region) rank globally for hypertension effective treatment coverage (controlled hypertension)?
- El Salvador ranks 9th and South-East Asia (WHO region) ranks 9th of 193 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hypertension effective treatment coverage (controlled hypertension )among adults aged 30-79, age-standardized (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.